

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 September 2024 (12.09.2024)



(10) International Publication Number
WO 2024/184351 A1

(51) International Patent Classification:

A61K 47/60 (2017.01) *A61K 47/68* (2017.01)
A61K 47/54 (2017.01) *A61P 3/10* (2006.01)
A61K 47/61 (2017.01) *A61K 47/59* (2017.01)

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2024/055724

(22) International Filing Date:

05 March 2024 (05.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23160258.2 06 March 2023 (06.03.2023) EP
23195412.4 05 September 2023 (05.09.2023) EP
23203735.8 16 October 2023 (16.10.2023) EP

(71) Applicant: **ASCENDIS PHARMA A/S** [DK/DK]; Tuborg Boulevard 12, 2900 Hellerup (DK).

(72) Inventors: **SPROGØE, Kennett**; c/o Ascendis Pharma A/S, Tuborg Boulevard 12, 2900 Hellerup (DK). **BISEK, Nicola**; c/o Ascendis Pharma GmbH, Im Neuenheimer Feld 584, 69120 Heidelberg (DE). **STUBBA, Daniel**; c/o Ascendis Pharma GmbH, Im Neuenheimer Feld 584, 69120 Heidelberg (DE). **REISACHER, Ulrike**; c/o Ascendis Pharma GmbH, Im Neuenheimer Feld 584, 69120 Heidelberg (DE). **WEISBROD, Samuel**; c/o Ascendis Pharma GmbH, Im Neuenheimer Feld 584, 69120 Heidelberg (DE).

(74) Agent: **BÜCHEL, Edwin**; Patentanwälte Isenbruck Bösl Hörschler PartG mbB, Seckenheimer Landstraße 4, 68163 Mannheim (DE).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

WO 2024/184351 A1

(54) Title: COMPOUNDS OF DRUGS WITH AN ALBUMIN BINDING MOIETY

(57) Abstract: The present application relates to compounds or pharmaceutically acceptable salts thereof, wherein the compounds comprise at least one polymeric moiety, to which at least two drug moieties are covalently and reversibly conjugated, which drug moieties are conjugated to an albumin binding moiety. The application also relates to pharmaceutical compositions comprising at least one such compound and their medical uses.